How much funding has Galecto raised?

Galecto has raised $446.9M in total funding, most recently a Series C round.

Who are Galecto's investors?

Galecto's investors include Soleus Capital, Ysios Capital, OrbiMed, Novo Nordisk Foundation, EIR Ventures, Cormorant Asset Management.

Where is Galecto headquartered?

Galecto is headquartered in Copenhagen, Denmark.

What industry is Galecto in?

Galecto operates in Biotech, Drug Development, Fibrosis, Therapeutics, Life Sciences.

Galecto

IPO

Redefining care for people with blood disorders

Public · Copenhagen, Denmark · Founded 2010 · $446.9M raised

Fibrosis

Headquarters: Copenhagen
Employees: 11–50
Founded: 2010
Business Model: B2B
Website: galecto.com

Total Funding: $446.9M
Last Round: $285.0M Series CNov 2025
Rounds: 4
Type: Public

About

Galecto is a clinical-stage biopharmaceutical company developing small-molecule and antibody therapeutics targeting galectin proteins for the treatment of fibrosis, cancer, and hematologic disorders. Its pipeline includes programs for idiopathic pulmonary fibrosis and myeloproliferative neoplasms. In March 2026 the company announced a name change to Damora Therapeutics following its acquisition of Damora Therapeutics and a strategic pivot to mutant calreticulin-driven blood disorders.

Summary

Galecto is a Biotech company based in Copenhagen, Denmark, founded in 2010. It has raised $446.9M in total across 4 rounds, most recently a $285.0M Series C round in Nov 2025. Investors include Soleus Capital, Ysios Capital and OrbiMed.

LinkedIn X (Twitter)